Zydus Lifesciences announced that the USFDA conducted a surveillance inspection at the group's API Unit, located at Dabhasa in Gujarat. The inspection was conducted from April 21st to 25th, 2025.
The inspection concluded with 6 observations and none of them were related to Data Integrity. The company is confident to address the observations expeditiously.

Low Price Shares
0 mins read . Dec 18, 2024

Nifty 50 Top 10 Stocks
0 mins read . Dec 18, 2024

Best Stocks in 2025
0 mins read . Dec 18, 2024

Explore our products
Unlimited Trading starting at ₹249
Open Trading Account